99mTc carbonyl DTPA-Rituximab: Preparation and preliminary bioevaluation

Applied Radiation and Isotopes

Volumn 86, Issue , 2014, Pages 52-56

  Pandey, Usha ^a   Kameswaran, Mythili ^a   Dev Sarma, Haladhar ^a   Samuel, Grace ^a  

^a BHABHA ATOMIC RESEARCH CENTRE   (India)

Author keywords

99mTc carbonyl DTPA Rituximab; Non Hodgkin's lymphoma (NHL); Radioimmunoscintigraphy; Rituximab

Indexed keywords

CD20 ANTIGEN; DIAGNOSTIC AGENT; MONOCLONAL ANTIBODY; RADIOPHARMACEUTICAL AGENT; RITUXIMAB; TECHNETIUM 99M CARBONYL DTPA RITUXIMAB; TECHNETIUM 99M CARBONYL DTPA-RITUXIMAB; TECHNETIUM COMPLEX;

(99M)TC CARBONYL-DTPA-RITUXIMAB; ANIMAL; ARTICLE; CHEMISTRY; METABOLISM; MOUSE; NON-HODGKIN'S LYMPHOMA (NHL); RADIOIMMUNOSCINTIGRAPHY; SYNTHESIS; TISSUE DISTRIBUTION;

(99M)TC CARBONYL-DTPA-RITUXIMAB; NON-HODGKIN'S LYMPHOMA (NHL); RADIOIMMUNOSCINTIGRAPHY; RITUXIMAB;

ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; MICE; ORGANOTECHNETIUM COMPOUNDS; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION;

EID: 84893413064     PISSN: 09698043     EISSN: 18729800     Source Type: Journal    
DOI: 10.1016/j.apradiso.2013.12.036     Document Type: Article

References (26)

1. 99mTc-carbonyls. Biopolymers 2004, 76:324-333.
2. -] in aqueous solution and its reaction with a bifunctional ligand. J. Am. Chem. Soc. 1998, 120:7987-7988.
3. Brady E.D., Chong H.S., Milenic D.E., Brechbiel M.W. Development of a spectroscopic assay for bifunctional ligand-protein conjugates based on copper. Nucl. Med. Biol. 2004, 31:795-802.
4. 99mTc(I) tricarbonyl ion. Appl. Radiat. Isot. 2008, 66:340-345.
5. 99mTc separation: An assessment of technology options. Nucl. Med. Biol. 2013, 40:167-176.
6. 99mTc using the tricarbonyl technology. Nucl. Med. Biol. 2011, 38:19-28.
7. Eckelman W.C. Unparalleled contribution of technetium-99m to medicine over 5 decades. JACC Cardiovasc. Imaging 2009, 2:364-368.
8. 99mTc-aqua ion labels peptide to an unprecedented high specific activity. J. Nucl. Med. 1999, 40:1913-1917.
9. Flieger D., Renoth S., Beier I., Sauerbruch T., Schmidt-Wolf I. Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDECC2B8in CD20-expressing lymphoma cell lines. Cell. Immunol. 2000, 204:55-63.
10. 99mTc-tricarbonyl labeled agents for cell labeling: development, biodistribution in normal mice and preliminary in vitro evaluation. Bioorg. Med. Chem. 2010, 18:396-402.
11. Goldsmith S.J. Radioimmunotherapy of lymphoma: Bexxar and Zevalin. Semin. Nucl. Med. 2010, 40:122-135.
12. Liu S. Bifunctional coupling agents for radiolabeling of biomolecules and target-specific delivery of metallic radionuclides. Adv. Drug Deliv. Rev. 2008, 60:1347-1370.
13. Lowry O.H., Rosebrough W.J., Farr A.L., Randal R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951, 193:265-275.
14. 99mTc-labeled Rituximab for imaging B lymphocyte infiltration in inflammatory autoimmune disease patients. Mol. Imaging Biol. 2012, 14:637-646.
15. Mather S.J., Ellison D. Reduction-mediated technetium-99m labeling of monoclonal antibodies. J. Nucl. Med. 1990, 31:692-697.
16. 227Th. Cancer Biother. Radiopharm. 2007, 22:469-479.
17. 99mTc(I) tricarbonyl core using a new bifunctional tridentate ligand. Nucl. Med. Commun. 2011, 32:324-329.
18. Pescovitz M.D. Rituximab, an anti-CD20 monoclonal antibody: history and mechanism of action. Am. J. Transplant. 2006, 6:859-866.
19. Press O.W., Farr A.G., Borroz K.I., Anderson S.K., Martin P.J. Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies. Cancer Res. 1989, 49:4906-4912.
20. 99mTc-labeled monoclonal antibody ior c5 in patients with colorectal and anal carcinomas: final report clinical trial phase I/II. Cancer Biol. Ther. 2007, 6:22-29.
21. 99mTc direct radiolabeling of PR81, a new anti-MUC1monoclonal antibody for radioimmunoscintigraphy. Iran. J. Nucl. Med. 2005, 23:7-16.
22. Srivastava S.C. Is there life after technetium: what is the potential for developing new broad based radionuclides. Semin. Nucl. Med. 1996, 26:119-131.
23. Stalteri M.A., Mather S.J. Technetium-99rn labeling of the anti-tumour antibody PRIA3 by photoactivation. Eur. J. Nucl. Med. 1996, 23:178-187.
24. 99mTc-labelled rituximab, a new Non-Hodgkin's lymphoma imaging agent: first clinical experience. Nucl. Med. Commun. 2008, 29:1059-1065.
25. 3-DTPA-folate as a folate receptor-targeted radiopharmaceutical. Nucl. Med. Biol. 2002, 29:569-573.
26. Waibel R., Alberto R., Willuda J., Finnern R., Schibli R., Stichelberger A., et al. Stable one-step technetium-99m labeling of His-tagged recombinant proteins with a novel Tc(I)-carbonyl complex. Nat. Biotechnol. 1999, 17:897-901.